Agent Repurposing for the Treatment of Advanced Stage Diffuse Large B-Cell Lymphoma Based on Gene Expression and Network Perturbation Analysis

Agent Repurposing for the Treatment of Advanced Stage Diffuse Large B-Cell Lymphoma Based on Gene Expression and Network Perturbation Analysis

Over 50% of diffuse large B-cell lymphoma (DLBCL) patients are diagnosed at an advanced stage. Although there are a few therapeutic strategies for DLBCL, most of them are more effective in limited-stage cancer patients. The prognosis of patients with advanced-stage DLBCL is usually poor with frequen...

Full description

Bibliographic Details
Main Authors: Chenxi Xiang, Huimin Ni, Zhina Wang, Binbin Ji, Bo Wang, Xiaoli Shi, Wanna Wu, Nian Liu, Ying Gu, Dongshen Ma, Hui Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Genetics
Subjects:
diffuse large B-cell lymphoma
drug repurposing
differentially expressed genes
differential module analysis
key driver analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fgene.2021.756784/full

Similar Items

Similar Items